Cargando…
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency
[Image: see text] Non-covalent inhibitors of the main protease (M(pro)) of SARS-CoV-2 having a pyridinone core were previously reported with IC(50) values as low as 0.018 μM for inhibition of enzymatic activity and EC(50) values as low as 0.8 μM for inhibition of viral replication in Vero E6 cells....
Autores principales: | Zhang, Chun-Hui, Spasov, Krasimir A., Reilly, Raquel A., Hollander, Klarissa, Stone, Elizabeth A., Ippolito, Joseph A., Liosi, Maria-Elena, Deshmukh, Maya G., Tirado-Rives, Julian, Zhang, Shuo, Liang, Zhuobin, Miller, Scott J., Isaacs, Farren, Lindenbach, Brett D., Anderson, Karen S., Jorgensen, William L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291137/ https://www.ncbi.nlm.nih.gov/pubmed/34408808 http://dx.doi.org/10.1021/acsmedchemlett.1c00326 |
Ejemplares similares
-
Potent Noncovalent Inhibitors of the Main Protease
of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel
Guided by Free Energy Perturbation Calculations
por: Zhang, Chun-Hui, et al.
Publicado: (2021) -
Identification of 14 Known Drugs as Inhibitors of
the Main Protease of SARS-CoV-2
por: Ghahremanpour, Mohammad M., et al.
Publicado: (2020) -
Anticancer metallohelices: nanomolar potency and high selectivity
por: Kaner, Rebecca A., et al.
Publicado: (2016) -
Nanomolar-Potency Small Molecule Inhibitor of STAT5
Protein
por: Cumaraswamy, Abbarna A., et al.
Publicado: (2014) -
Structure-Based Evaluation
of Non-nucleoside Inhibitors
with Improved Potency and Solubility That Target HIV Reverse Transcriptase
Variants
por: Frey, Kathleen M., et al.
Publicado: (2015)